Guo-ming P. Shi

Zhongshan, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 87 publications

Neoadjuvant GOLP in Intrahepatic Cholangiocarcinoma. Reply.

Neoadjuvant GOLP in Intrahepatic Cholangiocarcinoma. Reply.

Journal: The New England journal of medicine

Published: May 27, 2026

FGFR2 Fusion-Driven CXCL3 Downregulation Attenuates Neutrophil Recruitment in Intrahepatic Cholangiocarcinoma.

FGFR2 Fusion-Driven CXCL3 Downregulation Attenuates Neutrophil Recruitment in Intrahepatic Cholangiocarcinoma.

Journal: Cancer letters

Published: March 05, 2026

Neoadjuvant GOLP in Resectable High-Risk Intrahepatic Cholangiocarcinoma.

Neoadjuvant GOLP in Resectable High-Risk Intrahepatic Cholangiocarcinoma.

Journal: The New England journal of medicine

Published: March 04, 2026

Autophagy-promoted immunogenic cell death elicited by tyrosine kinase inhibitor orchestrates a synergistic immunotherapeutic microenvironment in hepatocellular carcinoma.

Autophagy-promoted immunogenic cell death elicited by tyrosine kinase inhibitor orchestrates a synergistic immunotherapeutic microenvironment in hepatocellular carcinoma.

Journal: Experimental hematology & oncology

Published: July 23, 2025

Tet2 deficiency-induced expansion of monocyte-derived macrophages promotes liver fibrosis.

Tet2 deficiency-induced expansion of monocyte-derived macrophages promotes liver fibrosis.

Journal: The Journal of experimental medicine

Published: May 31, 2025

Erratum: Mitogen-activated protein kinase kinase kinase 4 deficiency in intrahepatic cholangiocarcinoma leads to invasive growth and epithelial-mesenchymal transition.

Erratum: Mitogen-activated protein kinase kinase kinase 4 deficiency in intrahepatic cholangiocarcinoma leads to invasive growth and epithelial-mesenchymal transition.

Journal: Hepatology (Baltimore, Md.)

Published: April 07, 2025

HBV sequence integrated to enhancer acting as oncogenic driver epigenetically promotes hepatocellular carcinoma development.

HBV sequence integrated to enhancer acting as oncogenic driver epigenetically promotes hepatocellular carcinoma development.

Journal: Journal of experimental & clinical cancer research : CR

Published: March 08, 2025

Anti-PD1 antibody toripalimab combined with lenvatinib, or GEMOX chemotherapy combined with lenvatinib as first-line therapy in patients with advanced intrahepatic cholangiocarcinoma: a randomized, open, two-cohort Phase 2 Study.

Anti-PD1 antibody toripalimab combined with lenvatinib, or GEMOX chemotherapy combined with lenvatinib as first-line therapy in patients with advanced intrahepatic cholangiocarcinoma: a randomized, open, two-cohort Phase 2 Study.

Journal: BMC medicine

Published: February 24, 2025

Erratum: Protein tyrosine phosphatase receptor S acts as a metastatic suppressor in hepatocellular carcinoma by control of epithermal growth factor receptor-induced epithelial-mesenchymal transition.

Erratum: Protein tyrosine phosphatase receptor S acts as a metastatic suppressor in hepatocellular carcinoma by control of epithermal growth factor receptor-induced epithelial-mesenchymal transition.

Journal: Hepatology (Baltimore, Md.)

Published: February 18, 2025

First-line tislelizumab and ociperlimab combined with gemcitabine and cisplatin in advanced biliary tract cancer (ZSAB-TOP): a multicenter, single-arm, phase 2 study.

First-line tislelizumab and ociperlimab combined with gemcitabine and cisplatin in advanced biliary tract cancer (ZSAB-TOP): a multicenter, single-arm, phase 2 study.

Journal: Signal transduction and targeted therapy

Published: February 10, 2025

Lysine-specific demethylase 1 deletion reshapes tumour microenvironment to overcome acquired resistance to anti-programmed death 1 therapy in liver cancer.

Lysine-specific demethylase 1 deletion reshapes tumour microenvironment to overcome acquired resistance to anti-programmed death 1 therapy in liver cancer.

Journal: Clinical and translational medicine

Published: October 13, 2024

Application of a single-cell-RNA-based biological-inspired graph neural network in diagnosis of primary liver tumors.

Application of a single-cell-RNA-based biological-inspired graph neural network in diagnosis of primary liver tumors.

Journal: Journal of translational medicine

Published: April 14, 2024

Showing 1-12 of 87

Last Updated: 09/26/2026